| Literature DB >> 18852892 |
Fernando E Herrera1, Alessandra Chesi, Katerina E Paleologou, Adrian Schmid, Adriana Munoz, Michele Vendruscolo, Stefano Gustincich, Hilal A Lashuel, Paolo Carloni.
Abstract
The interplay between dopamine and alpha-synuclein (AS) plays a central role in Parkinson's disease (PD). PD results primarily from a severe and selective devastation of dopaminergic neurons in substantia nigra pars compacta. The neuropathological hallmark of the disease is the presence of intraneuronal proteinaceous inclusions known as Lewy bodies within the surviving neurons, enriched in filamentous AS. In vitro, dopamine inhibits AS fibril formation, but the molecular determinants of this inhibition remain obscure. Here we use molecular dynamic (MD) simulations to investigate the binding of dopamine and several of its derivatives onto conformers representative of an NMR ensemble of AS structures in aqueous solution. Within the limitations inherent to MD simulations of unstructured proteins, our calculations suggest that the ligands bind to the (125)YEMPS(129) region, consistent with experimental findings. The ligands are further stabilized by long-range electrostatic interactions with glutamate 83 (E83) in the NAC region. These results suggest that by forming these interactions with AS, dopamine may affect AS aggregation and fibrillization properties. To test this hypothesis, we investigated in vitro the effects of dopamine on the aggregation of mutants designed to alter or abolish these interactions. We found that point mutations in the (125)YEMPS(129) region do not affect AS aggregation, which is consistent with the fact that dopamine interacts non-specifically with this region. In contrast, and consistent with our modeling studies, the replacement of glutamate by alanine at position 83 (E83A) abolishes the ability of dopamine to inhibit AS fibrillization.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18852892 PMCID: PMC2566601 DOI: 10.1371/journal.pone.0003394
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Dopamine docked onto AS: chemical formulas of the proposed dopamine forms binding to AS [42].
Figure 2Molecular dynamics simulations.
(A) The six most representative conformations of AS, as obtained by the cluster procedure (see Material and Methods) in complex with some of the ligands (in red color). The picture has been obtained after 6 ns MD simulations. In all circumstances, the 125–129 residues (blue licorice) are in contact with the ligands (all the resulting complexes are shown in Figure S3). (B) The 125-126-129 Cα angles show the smaller spread around its average value on all the stable complexes. Top. Conformation of the C-terminal region in the stable and unstable adducts. Middle: Average values of angles formed by Cα (n−n+1−n+4) on stable (left) and unstable (right) adducts. Bottom: standard deviation of those angles (the average is 28° for the stable adducts and 29° for the unstable adducts).
H-bond and hydrophobic contacts in Dopamine•AS ‘stable’ adducts.
| Hydrogen Bonds | Hydrophobic contacts | ||
| Repr. Cluster 1 (39%) | DCH | Met127(O)-DCH(N1), (D: 3.7±0.8 Å) | Tyr125, (D: 4.7±0.6 Å) |
| Ser129(O)-DCH(O1), (D: 4.2±0.5 Å) | Tyr136, (D: 6.4±0.6 Å) | ||
| DHI | Glu137(OE2)-DHI(N1), (D: 2.8±0.2 Å) | Lys80, (D: 4.0±0.3 Å) | |
| Asp135, (D: 7.0±0.3 Å) | |||
| Tyr136, (D: 9.9±0.5 Å) | |||
| DOP | Lys96, (D: 6.2±0.7 Å) | ||
| Val118, (D: 6.0±09 Å) | |||
| Pro120, (D: 5.4±0.5 Å) | |||
| DOP-H | Glu123(OE2)-DOP-H(O1), (D: 3.5±1.2 Å) | ||
| Glu123(OE2)-DOP-H(O2), (D: 3.0±0.6 Å) | |||
| DQ | Asp135(N)-DQ(O2), (D: 3.3±0.4 Å) | Ile112, (D: 6.6±0.7 Å) | |
| Gly111(O)-DQ(N1), (D: 3.9±1.0 Å) | Asp135, (D: 5.4±1.0 Å) | ||
| IQ | Thr81, (D: 4.0±0.2 Å) | ||
| LEUK | Glu131, (D: 7.4±2.2 Å) | ||
| Gly132, (D: 5.8±2.1 Å) | |||
| Repr. Cluster 2 (15%) | DOP-H | Ser129(O)-DOP-H(N1), (D: 3.7±0.9 Å) | Ser129, (D: 5.4±0.7 Å) |
| Glu131(O)-DOP-H(N1), (D: 2.8±0.2 Å) | |||
| Repr. Cluster 3 (7%) | DOP | Met127, (D: 7.8±2.4 Å) | |
| DQ | Thr81(N)-DQ(O2), (D: 4.6±0.5 Å) | Lys34, (D: 6.9±0.7 Å) | |
| IQ | Lys34, (D: 5.9±0.8 Å) | ||
| Repr. Cluster 4 (6%) | DCH | Ala90(N)-DCH(O1), (D: 3.3±0.7 Å) | Phe94, (D: 4.5±0.3 Å) |
| Lys97(NZ)-DCH(O2), (D: 3.0±0.5 Å) | Val118, (D: 5.7±0.6 Å) | ||
| Tyr136 (D: 6.3±0.5 Å) | |||
| DHI | Ala90, (D: 4.8±0.3 Å) | ||
| Phe94, (D: 6.5±0.5 Å) | |||
| Lys97, (D: 4.9±0.3 Å) | |||
| DOP | Gly68(N)-DOP(O1), (D: 3.4±0.4 Å) | Gly67, (D: 4.8±0.6 Å) | |
| His50, (D: 5.0±0.5 Å) | |||
| Val66, (D: 6.2±0.5 Å) | |||
| DOP-H | Thr92(O)-DOP-H(N1), (D: 3.5±0.8 Å) | Tyr125, (D: 5.5±0.7 Å) | |
| DQ | Gln134(NE2)-DQ(O2), (D: 3.5±0.5 Å) | Tyr39, (D: 4.7±0.3 Å) | |
| Val49, (D: 6.3±0.5 Å) | |||
| IQ | Glu123(OE2)-IQ(N1), (D: 3.2±0.8 Å) | Phe94, (D: 5.4±0.6 Å) | |
| Met116, (D: 5.5±0.7 Å) | |||
| Repr. Cluster 5 (4%) | DCH | Glu105(OE2)-DCH(N1), (D: 4.0±0.7 Å) | Asp115, (D: 4.8±0.4 Å) |
| Met116(O)-DCH(N1), (D: 3.5±0.4 Å) | Pro117, (D: 6.6±0.5 Å) | ||
| DOP-H | Glu105(OE2)-DOP-H(O1), (D: 2.5±0.1 Å) | Val118, (D: 6.0±0.6 Å) | |
| IQ | Tyr125, (D: 6.2±1.9 Å) | ||
| Repr. Cluster 6 (4%) | DCH | Ser129, (D: 6.3±1.2 Å) | |
| Tyr133, (D: 5.7±1.4 Å) | |||
| DHI | Gly41, (D: 6.4±0.8 Å) | ||
| Pro128, (D: 4.8±0.6 Å) | |||
| DOP | Ala89(O)-DOP(O1), (D: 3.5±0.9 Å) | Leu113, (D: 6.0±0.7 Å) | |
| Asp135, (D: 6.3±0.4 Å) | |||
| DOP-H | Asp98(OD1)-DOP-H(N1), (D: 2.9±0.4 Å) | Asn65, (D: 5.4±0.6 Å) | |
| Glu61, (D: 5.5±0.2 Å) | |||
| DQ | Ala89(O)-DQ(N1), (D: 3.3±0.5 Å) | Ala90, (D: 5.8±0.5 Å) | |
| Ser129, (D: 6.3±1.4 Å) | |||
| Tyr133, (D: 6.1±1.3 Å) | |||
| IQ | Ala56, (D: 5.5±1.0 Å) | ||
| Glu57, (D: 5.5±0.9 Å | |||
| MD Derived | DCH | Ala90, (D: 6.7±1.8 Å) | |
| DHI | Glu83, (D: 12.1±1.5 Å) | ||
| Ile88, (D: 5.1±0.5 Å) | |||
| DOP | Glu131(OE2)-DOP(O1), (D: 3.7±0.9 Å) | Gln134, (D: 8.4±1.5 Å) | |
| DOP-H | Glu110(OE2)-DOPH(O1), (D: 2.6±0.4 Å) | Gly111, (D: 4.9±1.8 Å) | |
| Glu114(OE2)-DOPH(N1), (D: 2.9±0.5 Å) | |||
| DQ | Asn122(ND2)-DQ(O1), (D: 3.9±0.8 Å) | Asp121, (D: 6.5±1.1 Å) |
Several of then shown interactions with the C-terminal region, including the 125YEMPS129 region.
The distance (D) in the hydrogen bond column was measured between the heavy atoms. The hydrophobic contacts were measured as the distance (D) between the center of mass of the ligand and the specific amino acid.
Figure 3In vitro fibrillization of α-synuclein.
(A) Kinetics of fibrillization of WT and mutant (E83A, E126A, S129A and Triple) α-synuclein under assembly conditions in absence or presence of an equimolar quantity of dopamine (DOP) as monitored by the enhancement in Thioflavin-T (ThT) fluorescence intensity over time. Data are expressed as the mean±SEM (Standard Error of the Mean) of 2 or 3 independent experiments. (B) Amount of soluble WT and mutant α-synuclein protein remaining in solution after 72 hrs incubation under assembly conditions in absence or presence of an equimolar quantity of DOP monitored by SDS-PAGE. (C) CD spectra of the soluble WT and mutant α-synuclein proteins remaining in solution after 72 hrs incubation under assembly conditions in absence (blue line) or presence (red line) of an equimolar quantity of DOP.
Figure 4TEM analysis: WT and mutant α-synuclein (E83A, E126A, S129A and Triple) filament assembly in absence or presence of an equimolar quantity of dopamine (DOP).
Proteins were incubated under assembly conditions for 72 hrs and analyzed by negative staining EM as described in Materials and Methods.